Etanercept and efalizumab treatment for high‐need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice

Abstract

Etanercept and efalizumab are effective and safe treatments of psoriasis, even in a high-need population. Etanercept was able to sustain the clinical improvement throughout 24 weeks, whereas efalizumab was not in 47% of subjects.

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

“…Of these, there were five grade A 2 studies on etanercept monotherapy [282][283][284][285][286], six grade B studies [287][288][289][290][291][292], and three grade C studies [293][294][295]. Of these, there were five grade A 2 studies on etanercept monotherapy [282][283][284][285][286], six grade B studies [287][288][289][290][291][292], and three grade C studies [293][294][295].…”

“…After 24 weeks, the proportion of patients with a PASI 75 improvement increased by 25 %, 44 % and 59 %. Berends et al, Gottlieb et al, Van de Kerkhof and Leonardi et al [282,283,286,287] In patients who were treated with etanercept the Dermatology Life Quality Index improved by around 50.8 % (25 mg 2 ϫ/weekly) and 61 % (50 mg 2 ϫ/weekly) compared with the placebo group [283].…”

Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients

“…High-need patients, defined as psoriasis subjects with a moderate to severe condition who have failed to respond to two systemic conventional therapies due to lack of efficacy, intolerance or contraindication, are eligible to receive biological therapies (2,3). Since the approval of biological therapies, concerns about safety have been raised.…”

Efficacy of systemic therapies for moderate‐to‐severe psoriasis: a systematic review and meta‐analysis of long‐term treatment

“…With adalimumab, 83% of patients showed a PASI 75 response 29 . PASI 75 response for etanercept varied between 25–75.3% dependent on dosages 30–32 . 50 mg twice weekly showed a response rate of 59% compared to etancercept 25 mg twice weekly with a response rate of 44–57% 31,32 .…”